Efficacy and Safety of Auto-FMT in Preventing aGVHD

NCT04745221 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Soochow University

Phase

Not applicable

Started

2021-03-01

Last updated

2026-06-01

Condition(s) studied

Graft Versus Host Disease, Acute

Investigational drug(s) / intervention(s)

autologous fecal bacteria

autologous fecal bacteria: autologous fecal bacteria transplantation

Study summary

To evaluation the efficacy and safety of autologous fecal bacteria transplantation in preventing acute graft versus host disease after haploidentical hematopoietic stem cell transplantation. Bone marrow transplant patients were recruited.

Eligibility

Sex

ALL

Min age

18 Years

Max age

60 Years

Healthy volunteers

Inclusion Criteria: * Haplo-HSCT patients; Bacteroidetes \>0.1%; inverse Simpson diversity ≥2 Exclusion Criteria: * Gastrointestinal diseases；Age\>60; or Age\<10；Probiotics or prebiotics were taken before enrollment

Primary outcome measure(s)

Acute Graft-Versus-Host Disease — 90 days after haploidentical hematopoietic stem cell transplantation

Trial sites (1)

Facility	City	Region	Status
Ye Zhao	Suzhou	Jiangsu	Recruiting

More The First Affiliated Hospital of Soochow University trials in China

A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML Recruiting

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML Starting soon

A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia Starting soon

N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy Active, not recruiting

CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04745221 on ClinicalTrials.gov ↗ ← All trials in China